Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMOE39X)

Drug Name
Piragliatin Drug Info
Synonyms GK2; R1440; RO4389620
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Therapeutic Class
Endocrine, nutritional and metabolic diseases
Cross-matching ID
PubChem CID
10432339
CAS Number
CAS 625114-41-2
TTD Drug ID
DMOE39X

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucokinase (GCK) TTDLNGZ HXK4_HUMAN Modulator [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Glucokinase (GCK) DTT GCK 2.722 4.76 1.848 3.945
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glucokinase (GCK) DTT GCK 2.72E-01 0.76 0.52
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.J Clin Endocrinol Metab.2010 Nov;95(11):5028-36.